15353-j-veluchamy

136 | Chapter 5 14. Lanier LL. NK cell receptors. Annu Rev Immunol (1998) 16 :359-93. Epub 1998/05/23. doi: 10.1146/ annurev.immunol.16.1.359. PubMed PMID: 9597134. 15. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16 (2):216-29. Epub 1975/08/15. PubMed PMID: 50294. 16. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 10 (3):230-52. doi: 10.1038/cmi.2013.10. 17. Hayakawa Y, Smyth MJ. Innate immune recognition and suppression of tumors. Advances in cancer research (2006) 95 :293-322. Epub 2006/07/25. doi: 10.1016/s0065-230x(06)95008-8. PubMed PMID: 16860661. 18. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 17 (4):678-89. Epub 2011/02/18. doi: 10.1158/1078-0432.ccr-10-2173. PubMed PMID: 21325295. 19. Larsen SK, Gao Y, Basse PH. NK Cells in the TumorMicroenvironment. Critical reviews in oncogenesis (2014) 19 (0):91-105. PubMed PMID: PMC4062922. 20. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nature immunology (2008) 9 (5):486-94. Epub 2008/04/22. doi: 10.1038/ni1580. PubMed PMID: 18425105. 21. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res (2011) 17 (19):6287-97. Epub 2011/08/17. doi: 10.1158/1078-0432.ccr-11-1347. PubMed PMID: 21844012; PubMed Central PMCID: PMCPmc3186830. 22. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. Journal of immunotherapy (Hagerstown, Md : 1997) (2000) 23 (1):154- 60. Epub 2000/02/25. PubMed PMID: 10687148. 23. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res (2004) 24 (3b):1861-71. Epub 2004/07/28. PubMed PMID: 15274367. 24. Veluchamy JP,Spanholtz J,TordoirM,ThijssenVL,HeidemanDAM,Verheul HMW,et al. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE (2016) 11 (6):e0157830. doi: 10.1371/journal.pone.0157830. 25. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One (2010) 5 (2):e9221. Epub 2010/02/20. doi: 10.1371/ journal.pone.0009221. PubMed PMID: 20169160; PubMed Central PMCID: PMCPmc2821405. 26. Wurdinger T, Badr C, Tannous B. Gaussia luciferase blood level as an index of cell growth and proliferation. (2008).